REPROCELL Submits Application for Stem Cell Therapy Stemchymal in Japan for Spinocerebellar Ataxia SCA3 and SCA6
Key Insights
REPROCELL Inc. (search) has submitted an application for manufacturing and marketing approval in Japan for Stemchymal, a regenerative medicine product targeting spinocerebellar ataxia (search) types SCA3 and SCA6.
Stemchymal was granted Orphan Regenerative Medicine Product designation by Japan's MHLW in December 2018, qualifying it for PMDA priority review with a nine-month target review period.
The therapy aims to suppress the progression of ataxia in patients with SCA3 and SCA6, addressing a profound unmet medical need where limited effective treatments currently exist.
REPROCELL Inc. (search) announced on June 24, 2026, the submission of an application for manufacturing and marketing approval in Japan for Stemchymal, a regenerative medicine product targeting spinocerebellar ataxia (search) types SCA3 and SCA6. The Yokohama-based company holds exclusive commercialization rights for the therapy in Japan, marking a significant regulatory milestone for a disease with few available treatment options.
Chikafumi Yokoyama, CEO of REPROCELL, stated: "We are highly pleased to announce the submission of the application for manufacturing and marketing approval for Stemchymal for the treatment of spinocerebellar ataxia (search) (SCA3 and SCA6). Spinocerebellar ataxia is a designated intractable disease characterized by the progressive loss of motor function. With currently limited effective treatments available, there has been a profound unmet medical need for new therapeutic options."
The CEO further emphasized the company's conviction in the therapy's potential: "We firmly believe that Stemchymal has the potential to significantly contribute to slowing symptom progression and improving the quality of life (QOL) for these patients. Moving forward, our entire organization remains steadfast in our commitment to securing approval and delivering this groundbreaking therapy to patients as quickly as possible."
Orphan Designation and Regulatory Pathway
Stemchymal was granted Orphan Regenerative Medicine Product designation by Japan's Ministry of Health, Labour and Welfare (MHLW) in December 2018. To qualify for this designation, a product must target a disease affecting fewer than 50,000 patients in Japan, with either no appropriate alternative treatments available or the expectation of significantly higher efficacy or safety compared to existing therapies. Products receiving this designation are eligible for comprehensive support measures, including priority clinical trial consultations and priority review by the Pharmaceuticals and Medical Devices Agency (PMDA).
As a result of the orphan designation, Stemchymal is eligible for priority review by the PMDA, with a target regulatory review period of nine months from acceptance of the application.
Manufacturing and Commercialization Framework
Under the established framework, Stemchymal will be manufactured by Taiwan-based Steminent Biotherapeutics Inc., while REPROCELL will oversee all sales and distribution activities within Japan. This partnership structure leverages Steminent's manufacturing capabilities alongside REPROCELL's commercial infrastructure in the Japanese market.
Financial Outlook
REPROCELL indicated that the impact of this regulatory submission on the company's consolidated financial performance for the current fiscal year ending March 31, 2027, is expected to be minimal. However, the company views this milestone as a significant catalyst that will substantially contribute to further growth and the sustainable enhancement of corporate value over the medium to long term. REPROCELL stated it will promptly disclose any future material developments as they arise.